Moderna, Inc. (NASDAQ:MRNA) CEO Stephane Bancel Sells 40,000 Shares

Moderna, Inc. (NASDAQ:MRNAGet Rating) CEO Stephane Bancel sold 40,000 shares of the company’s stock in a transaction that occurred on Thursday, September 22nd. The stock was sold at an average price of $124.75, for a total value of $4,990,000.00. Following the sale, the chief executive officer now directly owns 5,411,946 shares of the company’s stock, valued at approximately $675,140,263.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Stephane Bancel also recently made the following trade(s):

  • On Thursday, September 15th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $137.11, for a total value of $5,484,400.00.
  • On Wednesday, September 7th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $133.68, for a total value of $5,347,200.00.
  • On Wednesday, August 24th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $142.21, for a total value of $5,688,400.00.
  • On Wednesday, August 17th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $159.03, for a total value of $6,361,200.00.
  • On Wednesday, August 10th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $172.29, for a total value of $6,891,600.00.
  • On Thursday, August 4th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $192.94, for a total value of $7,717,600.00.
  • On Thursday, July 28th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $156.73, for a total value of $6,269,200.00.
  • On Thursday, July 21st, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $168.11, for a total value of $6,724,400.00.
  • On Wednesday, July 13th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $172.69, for a total value of $6,907,600.00.
  • On Thursday, July 7th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $171.00, for a total value of $6,840,000.00.

Moderna Price Performance

Moderna stock traded down $0.68 during mid-day trading on Friday, hitting $123.64. 3,846,408 shares of the company were exchanged, compared to its average volume of 6,482,469. The company has a quick ratio of 1.71, a current ratio of 1.99 and a debt-to-equity ratio of 0.04. The business has a fifty day moving average of $152.65 and a 200 day moving average of $150.76. Moderna, Inc. has a 1-year low of $115.61 and a 1-year high of $453.61. The company has a market capitalization of $49.18 billion, a PE ratio of 3.72, a price-to-earnings-growth ratio of 0.73 and a beta of 1.69.

Moderna (NASDAQ:MRNAGet Rating) last released its quarterly earnings data on Wednesday, August 3rd. The company reported $5.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.73 by $0.51. Moderna had a return on equity of 94.76% and a net margin of 61.12%. The firm had revenue of $4.73 billion during the quarter, compared to analyst estimates of $3.95 billion. During the same period in the prior year, the company posted $6.46 earnings per share. The business’s revenue for the quarter was up 8.7% compared to the same quarter last year. As a group, sell-side analysts expect that Moderna, Inc. will post 26.41 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of MRNA. Norges Bank acquired a new position in Moderna during the fourth quarter worth $773,229,000. Coatue Management LLC increased its stake in shares of Moderna by 61.6% in the first quarter. Coatue Management LLC now owns 6,928,147 shares of the company’s stock valued at $1,193,443,000 after buying an additional 2,641,144 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Moderna by 108.2% in the first quarter. Renaissance Technologies LLC now owns 3,818,180 shares of the company’s stock valued at $657,720,000 after buying an additional 1,984,458 shares in the last quarter. Theleme Partners LLP increased its stake in shares of Moderna by 26.2% in the first quarter. Theleme Partners LLP now owns 6,336,940 shares of the company’s stock valued at $1,091,601,000 after buying an additional 1,314,766 shares in the last quarter. Finally, BlackRock Inc. increased its stake in shares of Moderna by 3.7% in the first quarter. BlackRock Inc. now owns 28,671,935 shares of the company’s stock valued at $4,939,029,000 after buying an additional 1,010,462 shares in the last quarter. 60.76% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Morgan Stanley reduced their price objective on Moderna from $199.00 to $197.00 and set an “equal weight” rating for the company in a research report on Thursday, August 4th. Argus reduced their price objective on Moderna from $180.00 to $150.00 and set a “buy” rating for the company in a research report on Wednesday, September 14th. SVB Leerink upped their target price on Moderna from $70.00 to $77.00 and gave the company an “underperform” rating in a research note on Monday, August 1st. Finally, Deutsche Bank Aktiengesellschaft upgraded Moderna from a “hold” rating to a “buy” rating and upped their target price for the company from $155.00 to $165.00 in a research note on Wednesday, September 7th. One research analyst has rated the stock with a sell rating, six have given a hold rating and five have issued a buy rating to the company. According to MarketBeat, Moderna currently has an average rating of “Hold” and a consensus price target of $211.08.

About Moderna

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Read More

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.